2 ms·
The vaccine did not take off and sat of the shelf because Ebola was "rare". It would have been ready for licensing by 2010-11. http://nytimes.com/2014/10/24/he
by denzil_correa 12y ago
The vaccine did not take off and sat of the shelf because Ebola was "rare". It would have been ready for licensing by 2010-11.
http://nytimes.com/2014/10/24/health/without-lucrative-market-potential-ebola-vaccine-was-shelved-for-years.html?referrer=&_r=2 http://nytimes.com/2014/10/24/health/without-lucrative-marke...
- ams6110 12y agoEbola was (and still is, compared to e.g. malaria) rare, no scare quotes needed. Until the latest outbreak in west Africa, Ebola infections were limited to handfuls of people. Not surprising that the developers of this vaccine did not take it through the gauntlet of expensive approvals, clinical trials, etc. that would be required to get it on the market.
- hga 12y agoNot quite "handfuls", but the official outbreak numbers for the Zaire strain, the one causing the current epidemic, never went higher than 318. It should be noted that clinical trials for vaccines are the most rigorous, because they are for healthy people.